Shiode Y, Kodama T, Sato Y, Takahashi R, Matsumae T, Shirai K
Biomark Res. 2025; 13(1):37.
PMID: 40038575
PMC: 11877696.
DOI: 10.1186/s40364-025-00752-8.
Yu Z, Fang Z, Yu Y, Liu S, Wang K, Shi Z
J Hepatocell Carcinoma. 2025; 12:183-192.
PMID: 39902378
PMC: 11789503.
DOI: 10.2147/JHC.S493094.
Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M
Signal Transduct Target Ther. 2025; 10(1):24.
PMID: 39809756
PMC: 11733248.
DOI: 10.1038/s41392-024-02097-4.
Yang C, Xiang W, Wu Z, Li N, Xie G, Huang J
BMC Cancer. 2025; 25(1):55.
PMID: 39789507
PMC: 11720332.
DOI: 10.1186/s12885-024-13399-9.
Lam W, Gabernet G, Poth T, Sator-Schmitt M, Oquendo M, Kast B
EMBO Rep. 2025; 26(3):880-907.
PMID: 39747668
PMC: 11811172.
DOI: 10.1038/s44319-024-00356-7.
Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial.
Yim S, Lee S, Baek S, Sohn B, Jeong Y, Kang S
Clin Mol Hepatol. 2024; 30(4):807-823.
PMID: 39038962
PMC: 11540371.
DOI: 10.3350/cmh.2024.0333.
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).
Lopez Lopez C, Calvo M, Camara J, Garcia-Paredes B, Gomez-Martin C, Lopez A
Clin Transl Oncol. 2024; 26(11):2800-2811.
PMID: 38914756
PMC: 11467113.
DOI: 10.1007/s12094-024-03568-4.
Macrophages Orchestrate the Liver Tumor Microenvironment.
Quaranta V, Ballaro C, Giannelli G
Cancers (Basel). 2024; 16(9).
PMID: 38730724
PMC: 11083142.
DOI: 10.3390/cancers16091772.
Hepatocellular Carcinoma: Current Drug Therapeutic Status, Advances and Challenges.
Zheng S, Chan S, Liu F, Liu J, Chow P, Toh H
Cancers (Basel). 2024; 16(8).
PMID: 38672664
PMC: 11048862.
DOI: 10.3390/cancers16081582.
Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc.
Bakiri L, Hasenfuss S, Guio-Carrion A, Thomsen M, Hasselblatt P, Wagner E
Proc Natl Acad Sci U S A. 2024; 121(18):e2404188121.
PMID: 38657045
PMC: 11067056.
DOI: 10.1073/pnas.2404188121.
ZBTB7B is a permissive regulator of hepatocellular carcinoma initiation by repressing c-Jun expression and function.
Zhu Y, Wang Q, Xie X, Ma C, Qiao Y, Zhang Y
Cell Death Dis. 2024; 15(1):55.
PMID: 38225233
PMC: 10789742.
DOI: 10.1038/s41419-024-06441-y.
New and Old Key Players in Liver Cancer.
Cuesta A, Palao N, Bragado P, Gutierrez-Uzquiza A, Herrera B, Sanchez A
Int J Mol Sci. 2023; 24(24).
PMID: 38138981
PMC: 10742790.
DOI: 10.3390/ijms242417152.
Preoperative Locoregional Therapy May Relate with Stemness and Distinct Transitions Between Epithelial and Mesenchymal States in Hepatocellular Carcinoma.
Espirito Santo J, Ladeirinha A, Alarcao A, Strelet E, Reis M, Santos R
J Clin Exp Hepatol. 2023; 14(1):101268.
PMID: 38076372
PMC: 10709210.
DOI: 10.1016/j.jceh.2023.08.004.
LINC02362/hsa-miR-18a-5p/FDX1 axis suppresses proliferation and drives cuproptosis and oxaliplatin sensitivity of hepatocellular carcinoma.
Quan B, Liu W, Yao F, Li M, Tang B, Li J
Am J Cancer Res. 2023; 13(11):5590-5609.
PMID: 38058825
PMC: 10695789.
Proliferative hepatocellular carcinomas in cirrhosis: patient outcomes of LI-RADS category 4/5 and category M.
Heo S, Kang H, Choi S, Kim S, Yoo Y, Choi W
Eur Radiol. 2023; 34(5):2974-2985.
PMID: 37848775
DOI: 10.1007/s00330-023-10305-y.
Advances in Histological and Molecular Classification of Hepatocellular Carcinoma.
Choi J, Thung S
Biomedicines. 2023; 11(9).
PMID: 37761023
PMC: 10526317.
DOI: 10.3390/biomedicines11092582.
Characterization and therapeutic perspectives of differentiation-inducing therapy in malignant tumors.
Zhu K, Xia Y, Tian X, He Y, Zhou J, Han R
Front Genet. 2023; 14:1271381.
PMID: 37745860
PMC: 10514561.
DOI: 10.3389/fgene.2023.1271381.
Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.
Tamura Y, Ono A, Nakahara H, Hayes C, Fujii Y, Zhang P
Cancers (Basel). 2023; 15(17).
PMID: 37686510
PMC: 10486496.
DOI: 10.3390/cancers15174234.
Hepatocellular Carcinoma: Past and Present Challenges and Progress in Molecular Classification and Precision Oncology.
Coffin P, He A
Int J Mol Sci. 2023; 24(17).
PMID: 37686079
PMC: 10487618.
DOI: 10.3390/ijms241713274.
Clinically conserved genomic subtypes of gastric adenocarcinoma.
Jeong Y, Eun Y, Lee S, Kang S, Yim S, Kim E
Mol Cancer. 2023; 22(1):147.
PMID: 37674200
PMC: 10481468.
DOI: 10.1186/s12943-023-01796-w.